Compare Gilead Sciences, Inc. (GILD) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs United States Natural Gas Fund — how do they compare? Gilead Sciences, Inc. trades at $136.15 (market cap $163.51B), while United States Natural Gas Fund trades at $10.41. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while United States Natural Gas Fund pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals.
| GILD | UNG | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Commodities - Energy |
52-Week High | $155.80 | $16.90 |
52-Week Low | $108.22 | $10.15 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
The United States Natural Gas Fund (UNG) is currently trading at $10.24, down 2.66% on the day. Technical indicators show a bearish trend with moving averages signaling strong selling pressure, though short-term oscillators like the RSI suggest potential oversold conditions. Recent news highlights natural gas price volatility driven by weather forecasts, LNG export flows, and weekly storage reports. As an exchange-traded fund tracking natural gas futures, UNG's performance is directly tied to commodity price movements rather than company fundamentals.
UNG presents a high-risk, speculative opportunity for investors seeking exposure to natural gas price movements. The fund's structure subjects it to contango-related decay in futures markets, which has historically eroded long-term value. While short-term price movements offer trading opportunities, structural challenges and commodity volatility create significant risks for buy-and-hold investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
